BlackRock Group’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

BlackRock Group’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$1.61M	Buy	14,846 +3,989	+37%	+$475K	﹤0.01%	1903
2016 Q3	$1.79M	Sell	10,857 -891	-8%	-$140K	﹤0.01%	1699
2016 Q2	$1.68M	Sell	11,748 -1,326	-10%	-$193K	﹤0.01%	1657
2016 Q1	$1.68M	Buy	13,074 +2,188	+20%	+$258K	﹤0.01%	1641
2015 Q4	$1.63M	Buy	10,886 +115	+1%	+$19.5K	﹤0.01%	1604
2015 Q3	$1.79M	Buy	10,771 +529	+5%	+$116K	﹤0.01%	1570
2015 Q2	$2.47M	Buy	10,242 +1,989	+24%	+$530K	﹤0.01%	1441
2015 Q1	$2.33M	Buy	8,253 +2,064	+33%	+$447K	﹤0.01%	1416
2014 Q4	$965K	Buy	6,189 +626	+11%	+$116K	﹤0.01%	1900
2014 Q3	$1.32M	Sell	5,563 -8,123	-59%	-$2.07M	﹤0.01%	1622
2014 Q2	$3.24M	Buy	13,686 +11,599	+556%	+$3.06M	﹤0.01%	1276
2014 Q1	$688K	Buy	+2,087	New	+$704K	﹤0.01%	2134

Other funds holding ICPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

BlackRock Group's ICPT Position: Q4 2016 in Review

BlackRock Group increased its Intercept Pharmaceuticals, Inc. (ICPT) stake by 37% in Q4 2016, buying an estimated $475K and bringing the position to 14,846 shares worth $1.61M. The position accounts for ﹤0.01% of the portfolio, ranked #1903.

BlackRock Group first reported a position in ICPT in Q1 2014 and has held it in 12 quarters since. The position peaked at $3.24M in Q2 2014. 159 funds tracked by Wall St. Rank hold ICPT as of Q4 2016.

BlackRock Group held 14,846 shares of Intercept Pharmaceuticals, Inc. worth $1.61M as of Q4 2016.
BlackRock Group bought 3,989 Intercept Pharmaceuticals, Inc. shares in Q4 2016, an estimated $475K.
Intercept Pharmaceuticals, Inc. made up ﹤0.01% of BlackRock Group's portfolio in Q4 2016, its #1903 holding.
BlackRock Group first reported a position in Intercept Pharmaceuticals, Inc. in Q1 2014 and has held it in 12 quarters since.
BlackRock Group's Intercept Pharmaceuticals, Inc. position peaked at $3.24M in Q2 2014.
159 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2016.

Based on BlackRock Group's 13F filing for Q4 2016, filed 10 Feb 2017.